<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00598533</url>
  </required_header>
  <id_info>
    <org_study_id>GE IDE No. S02907</org_study_id>
    <nct_id>NCT00598533</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Rapamycin- vs. Zotarolimus-Eluting Stents to Reduce Coronary Restenosis</brief_title>
  <acronym>ISAR-TEST-5</acronym>
  <official_title>Prospective, Randomized Trial of Rapamycin- and Zotarolimus-eluting Stents for the Reduction of Coronary Restenosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Deutsches Herzzentrum Muenchen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Deutsches Herzzentrum Muenchen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to evaluate the efficacy of Rapamycin- and Zotarolimus-Eluting
      stents for the reduction of Coronary Restenosis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective, randomized trial will compare the efficacy and safety of a Rapamycin plus
      Probucol-eluting stent with a polymer based Zotarolimus-eluting stent. Patients with
      symptomatic coronary artery disease without cardiogenic shock who will undergo coronary
      angiography and willing to participate in the trial will receive a loading dose of 600mg
      clopidogrel at least 2 hours before the procedure. They will be randomized to receive one of
      the above mentioned stents.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>A composite endpoint of cardiac death, myocardial infarction related to the target vessel or target lesion revascularisation</measure>
    <time_frame>at one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Late luminal loss</measure>
    <time_frame>at 6-8 months follow-up angiography</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stent thrombosis</measure>
    <time_frame>at one year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3002</enrollment>
  <condition>Coronary Heart Disease</condition>
  <arm_group>
    <arm_group_label>Dual-DES</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rapamycin + Probucol-eluting stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZES</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Polymer based Zotarolimus-eluting stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Rapamycin + Probucol-eluting stent (ISAR stent)</intervention_name>
    <description>due to randomization, Rapamycin- + Probucol-eluting stent will be implanted</description>
    <arm_group_label>Dual-DES</arm_group_label>
    <other_name>ISAR stent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>polymer based Zotarolimus-eluting stent (Endeavor Resolute)</intervention_name>
    <description>due to randomization, Zotarolimus-eluting stent with polymer will be implanted</description>
    <arm_group_label>ZES</arm_group_label>
    <other_name>Endeavor Resolute</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients older than age 18 with ischemic symptoms or evidence of myocardial ischemia
             in the presence of â‰¥ 50% de novo stenosis located in native coronary vessels

          -  Written, informed consent by the patient or her/his legally-authorized representative
             for participation in the study

          -  In women with childbearing potential a negative pregnancy test is mandatory.

        Exclusion Criteria:

          -  Target lesion located in the left main trunk.

          -  Target lesion located in the bypass graft.

          -  In-stent restenosis.

          -  Cardiogenic shock.

          -  Malignancies or other comorbid conditions (for example severe liver, renal and
             pancreatic disease) with life expectancy less than 12 months or that may result in
             protocol non-compliance.

          -  Known allergy to the study medications: Clopidogrel, Rapamycin, Probucol, Zotarolimus,
             stainless steel or cobalt chrome.

          -  Inability to take clopidogrel for at least 6 months.

          -  Pregnancy (present, suspected or planned) or positive pregnancy test.

          -  Previous enrollment in this trial.

          -  Patient's inability to fully cooperate with the study protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adnan Kastrati, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Deutsches Herzzentrum Muenchen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medizinische Klinik, Klinikum rechts der Isar</name>
      <address>
        <city>Muenchen</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum Muenchen</name>
      <address>
        <city>Munich</city>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2008</study_first_submitted>
  <study_first_submitted_qc>January 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2008</study_first_posted>
  <last_update_submitted>January 3, 2012</last_update_submitted>
  <last_update_submitted_qc>January 3, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Restenosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Probucol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

